Advertisement

Upstream Therapy in the Treatment of Atrial Fibrillation

  • Cristian Baicus
Chapter
Part of the Current Cardiovascular Therapy book series (CCT)

Abstract

Nonelectrical factors which lead to inflammation and fibrosis and ultimately to structural remodelling have an important role in the generation of atrial fibrillation. Experimental studies and then observational and post hoc analyses of randomized controlled trials with different endpoints showed that the blockers of the renin-angiotensin-aldosteron system, the statins and the polyunsaturated fatty acids might prevent atrial remodelling and thus atrial fibrillation, being called upstream therapy. However, later large and valid studies did not confirm the efficacy of this upstream therapy.

Keywords

Atrial Fibrillation Primary Prevention Secondary Prevention Atrial Fibrillation Recurrence Systolic Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Burashnikov A, Antzelevitch C. Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther. 2011;132(3):300–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Van Gelder IC. Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue. Cardiovasc Res. 2007;74:8–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Murray KT, Mace LC, Yang Z. Non-antiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm. 2007;4:S88–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Dorian P, Singh BN. Upstream therapies to prevent AF. Eur Heart J Suppl. 2008;10:H11–31.CrossRefGoogle Scholar
  6. 6.
    Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008;10:238–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res. 2003;60:315–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33:2098–108.PubMedCrossRefGoogle Scholar
  10. 10.
    Burstein B, Nattel S. Atrial structural remodeling as an antiarrhythmic target. J Cardiovasc Pharmacol. 2008;52:4–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Liu T, Korantzopoulos P, Xu G, Shehata M, Li D, Wang Z, et al. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis. Europace. 2011;13:346–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Liu T, Li L, Korantzopoulos P, Goudevenos JA, Li G. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49:1642–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Loffredo L, Angelico F, Perri L, Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord. 2012;12:107.PubMedCrossRefGoogle Scholar
  14. 14.
    Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13:308–28.PubMedCrossRefGoogle Scholar
  15. 15.
    OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 25 July 2013.
  16. 16.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, for the GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.Google Scholar
  17. 17.
    Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.PubMedGoogle Scholar
  18. 18.
    Smit MD, Van Gelder IC. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther. 2009;7:763–78.PubMedCrossRefGoogle Scholar
  19. 19.
    Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European society of cardiology guidelines. Part II: secondary prevention. Europace. 2011;13:610–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Almroth H, Hoglund N, Boman K, Englund A, Jensen S, Kjellman B, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J. 2009;30:827–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011;161:993–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;12:1360–420.Google Scholar
  23. 23.
    Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010;304:2363–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Bianconi L, Calo L, Mennuni M, Santini L, Morosetti P, Azzolini P, et al. n-3 Polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace. 2011;13:174–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17.PubMedCrossRefGoogle Scholar
  26. 26.
    Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928–38.PubMedCrossRefGoogle Scholar
  27. 27.
    Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J. 2009;30:2327–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86–92.PubMedCrossRefGoogle Scholar
  30. 30.
    Patti G, Chello M, Candura D, Pasceri V, D’Ambrosio A, Covino E, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114:1455–61.PubMedCrossRefGoogle Scholar
  31. 31.
    GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17.PubMedCrossRefGoogle Scholar
  32. 32.
    Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, et al.; J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13:473–9.Google Scholar
  33. 33.
    Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5:43–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Marik PE, Fromm R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review. J Crit Care. 2009;24:458–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case–control study. Arch Intern Med. 2009;169:1677–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Madrid AH, Peng J, Zamora J, Marín I, Bernal E, Escobar C, et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol. 2004;27:1405–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152:217–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol. 2013;165:17–24.PubMedCrossRefGoogle Scholar
  39. 39.
    Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG. Systematic review and meta-analysis: renin-angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther. 2012;26:47–54.PubMedCrossRefGoogle Scholar
  40. 40.
    Bhuriya R, Singh M, Sethi A, Molnar J, Bahekar A, Singh PP, et al. Prevention of recurrent atrial fibrillation with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a systematic review and meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther. 2011;16:178–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15:36–43.PubMedCrossRefGoogle Scholar
  42. 42.
    Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299–307.PubMedCrossRefGoogle Scholar
  43. 43.
    Zhang Y, Zhang P, Mu Y, Gao M, Wang JR, Wang Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2010;88(4):521–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest. 2011;41:719–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Johnston K, Stephens S. Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on risk of atrial fibrillation before coronary artery bypass grafting. Ann Pharmacother. 2012;46:1239–44.PubMedCrossRefGoogle Scholar
  46. 46.
    Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, Madershahian N, et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg. 2009;138:678–86.PubMedCrossRefGoogle Scholar
  47. 47.
    Saso S, Vecht JA, Rao C, Protopapas A, Ashrafian H, Leff D, et al. Statin therapy may influence the incidence of postoperative atrial fibrillation: what is the evidence? Tex Heart Inst J. 2009;36:521–9.PubMedGoogle Scholar
  48. 48.
    Yin L, Wang Z, Wang Y, Ji G, Xu Z. Effect of statins in preventing postoperative atrial fibrillation following cardiac surgery. Heart Lung Circ. 2010;19:579–83.PubMedCrossRefGoogle Scholar
  49. 49.
    Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, et al.; PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ. 2011;342:d1250.Google Scholar
  50. 50.
    Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose–response meta-analysis. J Thorac Cardiovasc Surg. 2010;140(2):364–72.PubMedCrossRefGoogle Scholar
  51. 51.
    Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol. 2010;56:1099–109.PubMedCrossRefGoogle Scholar
  52. 52.
    Dong L, Zhang F, Shu X. Usefulness of statins pretreatment for the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgery. Ann Med. 2011;43:69–74.PubMedCrossRefGoogle Scholar
  53. 53.
    Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2012;74:744–56.PubMedCrossRefGoogle Scholar
  54. 54.
    Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013;28(1):7–18.PubMedCrossRefGoogle Scholar
  55. 55.
    Santangeli P, Ferrante G, Pelargonio G, Dello Russo A, Casella M, Bartoletti S, et al. Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review. Europace. 2010;12:649–54.PubMedCrossRefGoogle Scholar
  56. 56.
    Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev. 2012;4:CD008493.PubMedGoogle Scholar
  57. 57.
    Khawaja O, Gaziano JM, Djoussé L. A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation. J Am Coll Nutr. 2012;31:4–13.PubMedCrossRefGoogle Scholar
  58. 58.
    Cao H, Wang X, Huang H, Ying SZ, Gu YW, Wang T, et al. Omega-3 fatty acids in the prevention of atrial fibrillation recurrences after cardioversion: a meta-analysis of randomized controlled trials. Intern Med. 2012;51:2503–8.PubMedCrossRefGoogle Scholar
  59. 59.
    He Z, Yang L, Tian J, Yang K, Wu J, Yao Y. Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. Can J Cardiol. 2013;29:196–203.PubMedCrossRefGoogle Scholar
  60. 60.
    Liu T, Korantzopoulos P, Shehata M, Li G, Wang X, Kaul S. Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials. Heart. 2011;97:1034–40.PubMedCrossRefGoogle Scholar
  61. 61.
    Armaganijan L, Lopes RD, Healey JS, Piccini JP, Nair GM, Morillo CA. Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. Clinics (Sao Paulo). 2011;66:1923–8.Google Scholar
  62. 62.
    Benedetto U, Angeloni E, Melina G, Danesi TH, Di Bartolomeo R, Lechiancole A, et al. n-3 Polyunsaturated fatty acids for the prevention of postoperative atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown). 2013;14:104–9.CrossRefGoogle Scholar
  63. 63.
    Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.Google Scholar
  64. 64.
    American College of Cardiology Foundation, American Heart Association, European Society of Cardiology, Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:1916–26.PubMedCrossRefGoogle Scholar
  65. 65.
    Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al.; European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.Google Scholar
  66. 66.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Carol Davila University of Medicine and Pharmacy BucharestBucharestRomania
  2. 2.Department of Internal MedicineColentina University Hospital BucharestBucharestRomania

Personalised recommendations